perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

- Influence of ethnicity and consanguinity on the genetic architecture of Hypertrophic
   Cardiomyopathy: insights from an understudied population
- 3 Keywords: Egyptian Collaborative Cardiac Genomics Project, homozygosity, NGS

Mona Allouba,<sup>1,2,11,\*</sup> Roddy Walsh,<sup>2,3,11</sup> Alaa Afify,<sup>1</sup> Mohammed Hosny,<sup>1,4</sup> Sarah Halawa,<sup>1</sup> Aya
Galal,<sup>1</sup> Mariam Fathy,<sup>1</sup> Pantazis I. Theotokis,<sup>2</sup> Ahmed Boraey,<sup>1</sup> Amany Ellithy,<sup>1</sup> Rachel
Buchan,<sup>2,5</sup> Risha Govind,<sup>2,5,6,7</sup> Nicola Whiffin,<sup>2,5,8,</sup> Shehab Anwer,<sup>1</sup> Ahmed ElGuindy,<sup>1</sup> James
S. Ware,<sup>2,5,9,12</sup> Paul J.R. Barton, <sup>2,5,9,12</sup> Yasmine Aguib,<sup>1,2,12\*</sup>, Magdi Yacoub,<sup>1,2,10,12\*</sup>

- 9
- 10<sup>1</sup> Aswan Heart Centre, Aswan, Magdi Yacoub Heart Foundation, Egypt
- <sup>2</sup> National Heart and Lung Institute, Imperial College London, London, United Kingdom
- 12 <sup>3</sup> Department of Experimental Cardiology, Amsterdam UMC, the Netherlands
- <sup>4</sup> Cardiology Department, Kasr Al Aini Medical School, Cairo University
- <sup>5</sup> Royal Brompton & Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust,
   London, United Kingdom
- <sup>6</sup> Present affiliation: Institute of Psychiatry, Psychology and Neuroscience, King's College
   London, London, United Kingdom
- 18 <sup>7</sup> Present affiliation: National Institute for Health Research (NIHR) Biomedical Research
- Centre, South London and Maudsley NHS Foundation Trust and King's College London,London, United Kingdom
- <sup>8</sup> Present affiliation: Wellcome Centre for Human Genetics, University of Oxford, Oxford OX3
   7BN, United Kingdom
- <sup>9</sup> MRC London Institute of Medical Sciences, Imperial College London, London, United
   Kingdom
- <sup>10</sup> Harefield Heart Science Centre, United Kingdom
- 26

- 28
- 29
- 30
- 31
- 32
- 33
- -
- 34
- 35
- 36
- 00
- 37

<sup>&</sup>lt;sup>11</sup> These authors contributed equally

<sup>&</sup>lt;sup>12</sup> Senior author

<sup>\*</sup>Contrespondencepons new less her main housen centrie by peerieview and should be isseed ig lide cliftical practice.

# 38

#### 39 Abstract

40 Hypertrophic cardiomyopathy (HCM) is an inherited cardiac condition characterized by 41 phenotypic heterogeneity that could partly be explained by the variability in genetic variants 42 contributing to disease. Accurate interpretation of these variants constitutes a major challenge 43 for diagnosis and implementing precision medicine, especially in understudied populations. 44 Here, we leverage ancestry-matched Egyptian patients (n=514) and deeply-phenotyped 45 controls (n=400) to accurately define the genetic architecture of HCM. We also compare HCM variation between Egyptian and predominantly European patients to identify genetic features 46 47 unique to consanguineous populations in Middle East and North Africa (MENA), which are likely to represent important contributors to disease. We report a higher prevalence of 48 49 homozygous variants in Egyptian patients (4.1% vs 0.1%, p-value= $2x10^{-7}$ ), with variants in the 50 minor HCM genes MYL2, MYL3 and CSRP3 more likely to present in homozygosity than the 51 major genes (MYH7, MYBPC3), suggesting that these variants are less penetrant in 52 heterozygosity. Biallelic variants in the recessive HCM gene TRIM63 were detected in 2.1% 53 of patients (5-fold greater than European patients), highlighting the importance of recessive 54 inheritance/genes in consanguineous populations. Finally, significantly fewer rare variants 55 detected in Egyptian HCM patients could be classified as (likely) pathogenic compared to Europeans (40.8% vs. 61.6%, p-value=1.6x10<sup>-5</sup>) due to the underrepresentation of MENA 56 57 populations in current HCM databases. This proportion increased to 53.8% after incorporating 58 methods that compare variant frequencies between Egyptian patients and controls. Together, 59 our findings demonstrate that studying consanguineous populations reveals novel insights with relevance to genetic testing and our understanding of the genetic architecture of HCM. 60

- 61
- 62
- 63

## 65

#### Introduction 66

67 Hypertrophic cardiomyopathy (HCM [MIM: 192600] is a common inherited cardiac condition affecting at least 1:500 in the general population <sup>1,2</sup>. It is defined by left ventricular hypertrophy 68 69 (LVH) in the absence of other identifiable cardiac or systemic causes. Since its first description 70 in 1958, HCM has been considered as a highly heterogenous disease with regards to mode of inheritance, phenotype and genotype <sup>3–5</sup>. The genetic etiology of HCM is largely attributed 71 72 to variation in genes that encode components of the contractile apparatus (sarcomere) in 73 cardiac muscle cells.

74

Large HCM datasets from the Sarcomeric Human Cardiomyopathy Registry (SHaRe) and 75 76 other diverse ancestral HCM populations have provided strong evidence supporting diseaseassociated, long-term adverse clinical outcomes, including mortality <sup>6-11</sup>. With respect to 77 78 genotype, SHaRe demonstrated that patients with pathogenic sarcomere variants had an earlier onset of disease and were at a higher risk of developing adverse clinical outcomes <sup>10</sup>. 79 80 Given the interplay between genetics and disease progression, these patients may benefit 81 from effective treatments that delay or prevent HCM-related complications provided these 82 pathogenic variants are well characterized <sup>10,12</sup>. Although immense progress has been made 83 in elucidating the genetic determinants of HCM, much remains to be explored including 84 genetic-, environmental- and epigenetic factors influencing disease penetrance and 85 expressivity. Also, the rapid integration of genetic testing into everyday clinical practice has 86 resulted in the identification of a large number of variants of uncertain significance, which cannot be acted upon clinically<sup>10,13,14</sup>. This issue is more evident in underrepresented 87 populations, who are more likely to receive inconclusive genetic testing results, compared to 88 89 well-studied European-ancestry HCM patients <sup>15</sup>. Therefore, extending genomic research to 90 diverse ancestral populations will not only reduce health disparities as we move towards 91 precision-based HCM patient management but may also enhance variant interpretation for

diagnosis, and provide novel genetic and mechanistic insights into the disease. For example,
 we have recently reported the identification of a new class of HCM pathogenic variants in
 *MYH7*, which was enriched in Egyptian patients over ancestry-matched controls and absent
 from large-scale HCM patients of predominantly European ancestry <sup>16–18</sup>.

96

97 The aim of this study is to define the genetic architecture of HCM in the previously 98 understudied Egyptian population that is known to have a high rate of consanguinity <sup>19,20</sup>. This 99 study provides, to our knowledge, the largest and most comprehensive analysis of HCM in the 100 Middle East and North Africa (MENA) region to date. We leverage a prospective Egyptian 101 HCM cohort and an ancestry-matched, Egyptian healthy volunteer control cohort with 102 comprehensive cardiovascular phenotyping, to define the genetic architecture of HCM in 103 Egypt. In addition, we compare genetic data between Egyptian and well-characterized patients 104 of predominantly European ancestry to identify genetic features unique to consanguineous 105 populations of MENA ancestry which are likely to be important contributors of HCM.

106

# 107 Methods

# 108 Study population

# 109 Egypt HCM cohort

A prospective cohort of unrelated HCM patients (n=514) was recruited to the Aswan Heart
Centre (AHC), Egypt as part of the Egyptian Collaborative Cardiac Genomics (ECCO-GEN)
Project and the National HCM Registry. This cohort is hereafter referred to as Egypt HCM.
Clinical diagnosis of HCM was confirmed by echocardiography and/or Cardiac Magnetic
Resonance (CMR) imaging.

115

# 116 UK HCM cohort

A prospective cohort of HCM patients of predominantly European ancestry (n=684) was
recruited by the NIHR Cardiovascular Biomedical Research Unit at the Royal Brompton

Hospital (RBH), London <sup>21</sup>. This cohort is hereafter referred to as UK HCM. HCM diagnosis
was confirmed with CMR.

121

# 122 Egypt control cohort

Egyptian healthy volunteers (n=400) were recruited from across the country as part of the Egyptian Collaborative Cardiac Genomics (ECCO-GEN) Project aiming to study local genetic variation in 1000 healthy individuals <sup>17</sup>. All volunteers underwent detailed cardiovascular phenotyping, including clinical examination, 12-lead electrocardiogram, and CMR to confirm absence of CVD. This cohort is hereafter referred to as Egypt control.

128

# 129 UK control cohort

UK healthy volunteers (n=1,054) of predominantly European ancestry were recruited
 prospectively via advertisement for the UK Digital Heart Project at Imperial College London <sup>22</sup>.
 All volunteers, denoted hereafter as UK controls, underwent CMR to confirm the absence of
 cardiac disease.

Participants from all four cohorts provided informed consent and were approved by their localresearch ethics committees.

136

# 137 Gene selection:

138 DNA samples from the above-mentioned case and control cohorts were sequenced on 139 Illumina platforms (Miseq, Nextseq or Hiseq) and a subset of these on Life Technologies SOLiD 5500xl using cardiac gene panels including the TruSight Cardio Sequencing kit<sup>23</sup>. The 140 number of HCM patients and controls from the Egypt and UK cohorts analyzed for each gene 141 142 are depicted in Supplementary Table 1. Thirteen validated autosomal dominant HCM genes, 143 including sarcomere-encoding (ACTC1 (MIM: 102540), MYBPC3 (MIM: 600958), MYH7 (MIM:160760), MYL2 (MIM: 160781), MYL3 (MIM: 160790), TNNC1 (MIM: 191040), TNN/3 144 (MIM: 191044), TNNT2 (MIM: 191045) and TPM1 (MIM: 191010)) and non-sarcomere-145 encoding genes (PLN (MIM: 172405), ACTN2 (MIM: 102573), CSRP3 (MIM: 600824), JPH2 146

(MIM: 605267)) were analyzed <sup>21,24,25</sup>. Genes, which have been previously shown to account for less than 5% of HCM cases were defined in this work as "minor" genes <sup>18</sup>. *MYH7* and *MYBPC3* were defined here as "major" genes as they account for over 70% of identified pathogenic variants in HCM <sup>26</sup>. Separately, biallelic variants in the recently implicated recessive HCM gene *TRIM63* (MIM: 606131) were evaluated. Some genes recently identified as rarer causes of HCM (*ALPK3* (MIM: 617608), *FHOD3* (MIM: 609691, *FLNC* (MIM: 102565) were not included on the gene panels used in this study.

154

# 155 Rare variant filtering and classification

Rare variants in validated HCM genes were defined as having a filtering allele frequency (FAF) of  $\leq 4 \times 10^{-5}$  in gnomAD (v2.1.1) based on the statistical framework proposed by Whiffin *et al.*, 2017<sup>27</sup>. Variants were annotated by CardioClassifier based on rules defined by the American College of Medical Genetics and Genomics/Association of Molecular Pathology (ACMG-AMP) as Pathogenic (P), Likely Pathogenic (LP) and Uncertain Significance (VUS) (full details in Supplementary Methods)<sup>28,29</sup>. Detailed lists of all rare variants observed in the Egyptian and UK HCM and control cohorts are provided in Supplementary Tables 2-5.

163

# 164 Comparison of the genetic landscape of HCM between Egypt and UK HCM cohorts

First, the genetic architecture of the HCM in the Egyptian population was assessed by 165 166 comparing the frequency of rare variation in validated HCM genes between ancestry-matched 167 patients and controls. Second, the genetic landscape of HCM was compared between the 168 Egypt and UK HCM cohorts using their respective population-matched controls. For each 169 gene, the excess of rare variants in the Egypt HCM cohort over the Egypt control cohort was 170 compared with the excess of rare variants in the UK cohort over UK controls (Egypt HCM<sub>Control</sub> 171 excess vs. UK HCM<sub>Control</sub> excess). Third, the proportion of genotype-positive patients (i.e., 172 those carrying rare variants) attributable to each HCM gene was compared between the Egypt 173 and UK HCM cohorts.

Comparison of the proportion of clinically actionable variants between the Egypt and

# 175 UK HCM cohorts

The proportion of clinically actionable variants (i.e., P and LP) was evaluated in the Egypt HCM cohort by dividing the number of patients with P/LP variants by the total number of patients with rare variants in validated HCM genes. For patients with multiple hits (refer to Supplementary Tables 6 and 7), the variant with the highest pathogenicity was prioritized (i.e., P then LP then VUS). The proportion of clinically actionable variants was then compared between the Egypt and UK HCM cohorts.

182

174

# 183Application of the new Etiological Fraction (EF)-based American College of Medical184Genetics and Genomics/Association or Molecular Pathology (ACMG-AMP) rule on rare

185 MYH7 missense variants

The effect of the recently proposed EF-based ACMG/AMP rules by Walsh *et al.*, 2019 on the yield of actionable *MYH7* missense variants (i.e. P and LP) identified in the Egypt HCM cohort was assessed<sup>13</sup>.

189 First, we evaluated whether the regional distributions of pathogenic and benign variation in 190 MYH7, previously observed in European individuals, is also observed in Egyptians. The 191 frequency of rare missense MYH7 variants in the predefined patient-enriched HCM cluster (residues: 167-931) was calculated <sup>13</sup>. The distribution of rare missense *MYH7* variants in the 192 193 Egypt HCM and control cohorts and was visualized using the TrackViewer package (v 1.22.1) 194 in R statistical environment (v 3.6.3). This was further compared with the previously published 195 cohort of >6,000 HCM patients from Partners Laboratory of Molecular Medicine and Oxford Medical Genetics Laboratory (denoted here as LMM/OMGL)<sup>18</sup>. Second, the odds ratio (OR) 196 197 and etiological fraction (EF) (EF = (OR-1)/OR) for this cluster were calculated using the Eqypt 198 control cohort as the reference control population.

199

200 *MYH7* missense variants were classified as per the adopted new EF-based PM1\_strong rule,

201 which is activated if these variants are located in a protein region with EF $\ge$ 0.95

#### Results 202

#### 203 **Cohort characteristics**

- 204 The Egypt HCM cohort comprised 514 patients (67% male, 33% female; full details in
- Supplementary Table 8). Consanguinity was reported in 28.4% of Egyptian patients. Notably, 205
- 206 UK patients (n=684) were ca. 20 years older (mean onset age 55.5+15.5 years vs. 34.7 + 17.4
- years, p-value<2.2x10<sup>-16</sup>), presented with less severe hypertrophy (LVMWT: 18.9+4.4mm vs. 207
- 208 23.6+7mm, p-value=4.9x10<sup>-15</sup>) and showed a lower incidence of left ventricular outflow tract
- 209 obstruction (LVOTO) (24%) compared to Egyptian patients (36% vs. 73%, p-value<2.2x10<sup>-16</sup>).
- 210 A summary of the demographic- and cardiac characteristics of the Egypt and UK HCM cohorts
- 211 with available data is outlined in Table 1.
- 212

#### 213 Table 1: Demographic and cardiac characteristics of Egypt and UK HCM cohorts

General characteristics	Egypt HCM n(%)	UK HCM n(%)	p-value
Demographics			
Age (years) (mean (sd)) Male gender n(%) Offspring of Consanguineous Marriage* FH of HCM FH of SCD	34.7 <u>+</u> 17.4 345 (67.3%) 99 (28.4%) 111 (25.1%) 78 (17.6%)	55.5 <u>+</u> 15.5 473 (73.4%) N/A 127 (24.5%) 116 (25.2%)	<2.2x10 <sup>-16</sup> 0.02 N/A 0.88 0.01
Cardiac Characteristics			
LVMWT (mm)** (mean (sd)) Extreme LVMWT (>30mm) LVOTO (≥30mm Hg) LVEF (%)** (mean (sd)) Myectomy ICD implantation	23.6 <u>+</u> 7 54 (17.5%) 220 (72.8%) 71.5 <u>+</u> 13.3 168 (51.5%) 7 (2.7%)	18.9 <u>+</u> 4.4 8 (1.3%) 223 (36.1%) 74.3 <u>+</u> 8.5 N/A N/A	4.9x10 <sup>-15</sup> <2.2x10 <sup>-16</sup> <2.2x10 <sup>-16</sup> 0.004 N/A N/A

214 \*Consanguinity (self-reported) was defined as first-cousin marriage. FH: Family History, SCD: Sudden 215 Cardiac Death, LVMWT: Left Ventricular Maximal Wall Thickness, LVOTO: Left Ventricular Outflow 216 Tract Obstruction, LVEF: Left Ventricular Ejection Fraction, ICD: Implantable Cardioverter Defibrillator. 217 \*\*LVMWT and LVEF were measured in the Egypt HCM and UK HCM cohorts by echocardiography and

- 218 CMR, respectively.
- 219

#### 220 Differences in the genetic architecture of HCM between Egyptian- and UK patients

- 221 In order to evaluate the genetic architecture of HCM in Egypt, we compared the burden of rare
- 222 variation (gnomAD<sub>popmax</sub> FAF  $<4x10^{-5}$ ) in validated HCM genes between Egyptian patients and

controls (Figure 1A, left). The inclusion of ancestry-matched controls into this analysis enabled
 us to address the potential bias introduced by defining rare variants using gnomAD, which has
 minimal representation from the MENA region (Supplementary Figure 1).

226

227 In addition, we compared the genetic landscape of HCM between the Egypt and UK HCM 228 cohorts (using their respective population-matched controls), to directly compare the excess 229 burden of rare variants in HCM-associated genes in each cohort (labelled as Egypt HCM<sub>Control</sub> 230 excess and UK HCM<sub>control</sub> excess) (Figure 1A, right). A higher overall excess burden of rare variation was observed in the Egypt HCM cohort compared to UK HCM (52.7% vs. 32.0%) 231 232 (Figure 1A), with 1.6-fold more Egyptian patients carrying rare variants compared to UK HCM 233 (Figure 1B). We then performed a secondary analysis comparing the proportion of genotype-234 positive patients (i.e., those carrying rare variants) attributable to each HCM gene between 235 the Egypt and UK HCM cohorts (Figure 1C).

236

237 As expected, rare variants in both MYH7 and MYBPC3 accounted for the majority of rare 238 variation in both the Egypt and UK HCM cohorts (Table 2). MYBPC3 non-truncating variants 239 and PLN variants accounted for a higher proportion of genotype-positive patients in the UK 240 HCM cohort compared to Egyptian patients (MYBPC3: 26.9% vs. 13.7% and PLN: 0.92% vs. 241 0%) (Table 2). In contrast, MYH7 truncating variants accounted for a higher proportion of 242 genotype-positive patients in the Egypt HCM cohort, which is explained by the recurrent 243 variant c.5769delG [p.Ser1924AlafsTer9]. This variant was present in 3.3% of Egypt HCM 244 patients and we recently showed that it causes HCM by introducing a distal premature 245 termination codon, which escapes nonsense mediated decay resulting in the expression of an 246 abnormal protein<sup>16</sup>. Several recurrent truncating variants in *MYBPC3* were also detected, with 247 two of these (c.1516delG [p.Asp506ThrfsTer7] (0.97%, n=5) and c.534 541delGGCCGGCG 248 [p.Ala179GInfsTer59] (1.36%, n=7)) likely to be Egyptian/North African specific founder 249 variants. MYBPC3 founder variants have similarly been reported in numerous regions <sup>30</sup>.

250

Due to the limited number of observed variants, HCM genes encoding components of the thin filament (*ACTC1*, *TNNC1*, *TNNI3*, *TNNT2* and *TPM1*) and myosin light chain (MLC: *MYL2* and *MYL3*) were combined into groups based on their similar function. While rare variation in thin filament genes accounted for a relatively higher proportion of genotype-positive patients in the UK HCM cohort compared to Egypt HCM (12.3% vs. 6.6%), non-truncating variants in MLC genes accounted for a higher proportion of genotype-positive patients in the Egypt HCM cohort (9.96% vs. 2.28%) (Table 2).

258

259 Six distinct variants were identified in each of MYL2 (5 missense and 1 splice site) and MYL3 260 (6 missense) (Supplementary Table 2). Of these, three MYL2 variants were recurrently 261 observed in Egyptian patients (c.173G>A [p.Arg58Gln] (n=2,0.39%), c.450G>T 262 [p.Leu150Phe] (n=3,0.58%) and c.278C>T [p.Ala93Val] (n=5, 0.97%)). In MYL3 3/6 missense 263 variants observed in Egyptian patients were also recurrent (c.460C>T [p.Arg154Cys] 264 (n=2,0.39%), c.518T>C [p.Met173Thr] (n=4,0.78%) and c.508G>C [p.Glu170Gln] 265 (n=6.1.17%)). With the exception of the known pathogenic MYL2 p.Arg58GIn variant, these 266 recurrent variants were absent from both the UK HCM cohort and LMM/OMGL HCM cohorts. 267 Also, the *MYL2* variant p.Leu150Phe has not been previously reported whereas the other ten 268 MLC variants are currently classified as VUS in ClinVar.

269

For the non-sarcomeric HCM genes, rare variants in both *CSRP3* (truncating and nontruncating) and *JPH2* (non-truncating) showed a nominal enrichment in the genotype-positive Egypt HCM cohort compared to UK HCM (Table 2).

273

To explore why variants in some minor HCM genes (MLC, *CSRP3* and *JPH2*) seem to be more prevalent in the Egypt HCM cohort compared to UK HCM, we then examined the effect of consanguinity, and the frequency of homozygous variants, on this cohort.

277




Figure 1: Enrichment of rare variation in HCM minor genes (MLC, CSRP3 & JPH2) in the Egypt HCM cohort vs. UK HCM. A) The overall frequency of rare variants (gnomAD<sub>popmax</sub> FAF <4x10<sup>-5</sup>) in 13 validated HCM genes was compared between Egypt and UK HCM patients and controls. A 1.6 fold greater excess burden (i.e. total case frequency - total control frequency) was observed in the Egypt HCM cohort, which should be accounted for with the direct gene comparisons (B). B) Population-matched patients vs. control comparison (Egypt HCM<sub>Control</sub> excess and UK HCM<sub>Control</sub> excess) of genetic variation between Egypt and UK cohorts for each HCM gene/gene class. C) Comparison of the proportion of genotype-positive patients (i.e., those carrying rare variants) per HCM gene confirms the enrichment of rare variants in the HCM minor genes MLC (MYL2 & MYL3), CSRP3 and JPH2 in Egyptians (as observed in Figure B). Truncating and non-truncating variants (Figures A & B) are shown in red and grey, respectively. Thin filament: ACTC1, TNNC1, TNNI3, TNNT2, TPM1.

311 Table 2: Comparison of population-matched patient versus control excess frequencies (left) and

312 the proportion of genotype-positive patients between Egypt HCM and UK HCM cohorts (right)

313 for sarcomeric- and other validated HCM genes

Gene/Gene	Variant type		/ in patients vs. htrols	Proportion of all G+		
groups		Egypt HCM <sub>Control</sub> excess	UK HCM <sub>Control</sub> excess	Egypt HCM G+ prop	UK HCM G+ prop	
МҮН7	Non-truncating	13.95%	9.68%	30.26%	32.88%	
	Truncating	3.06%	0.01%	6.27%	0.91%	
МҮВРС3	Non-truncating	4.45%	6.73%	13.65%	26.94%	
	Truncating	9.34%	5.41%	17.71%	16.89%	
Myosin light chain (MLC)	Non-truncating	5.25%	0.26%	9.96%	2.28%	
	Truncating	0.19%	0.00%	0.37%	0%	
Thin Filament	Non-truncating	3.50%	3.38%	6.64%	12.33%	
	Truncating	0.00%	-0.09%	0%	0%	
CSRP3	Non-truncating	1.70%	0.49%	3.69%	1.83%	
	Truncating	0.72%	0.00%	1.85%	0%	
JPH2	Non-truncating	1.47%	0.29%	5.17%	1.37%	
	Truncating	0%	0%	0%	0%	
ACTN2	Non-truncating	-0.11%	0.51%	4.06%	3.65%	
	Truncating	0.19%	0%	0.37%	0%	
PLN	Non-truncating	0%	-0.23%	0%	0.46%	
FLIN	Truncating	0%	0.15%	0%	0.46%	

Comparison of the excess of rare (FAF<4x10<sup>-5</sup>) variation in HCM patients over controls for Egypt and UK cohorts, grouped by gene/gene class and variant class (left). Note - the overall case excess across the validated HCM genes/gene classes is 1.6 times greater in the Egypt cohort (Figure 1A), therefore any comparisons for specific genes or gene classes between Egypt and UK cohorts should take this into account. The proportion of genotype-positive (i.e., those with rare variants) Eqypt HCM and UK HCM patients per HCM gene is shown (left). RV: rare variants; G+: genotype-positive; prop: proportion.

- 314
- 315

#### 316 Higher burden of homozygous variants in the Egypt HCM cohort compared to UK HCM

- 317 In the Egypt HCM cohort, 28% of patients reported to have consanguineous parents. This
- 318 prompted us to evaluate the frequency of homozygous variants, both for rare variants
- $(FAF_{popmax} \leq 4.0 \times 10^{-5})$  and for low frequency variants sufficiently rare to cause biallelic disease 319
- (FAF<sub>popmax</sub>≤0.00126)<sup>27</sup>. The yield of homozygous variants was then compared with the UK 320
- 321 cohort.
- 322 As expected, homozygous variants were significantly more common in Egyptian patients
- 323 compared to UK, for both the rare  $(4.1\% (n=21) \text{ vs. } 0.1\% (n=1), p=2x10^{-7})$  and low frequency
- 324 (2.1% (n=11) vs. 0%, p=8.5x10<sup>-5</sup>) variants. Table 3 summarizes the homozygous variants
- 325 observed in Egyptian patients. Homozygous variants in these genes were not observed in

either the Egypt or UK control cohorts. Among Egypt HCM patients carrying homozygous
variants, 31.3% reported not having consanguineous parents (i.e. first cousins), which may
indicate an underreporting of consanguinity or more distantly related patients.

329

330 Two Egyptian patients presented with homozygous MYBPC3 truncating variants (c.1558G>T 331 [p.Glu520Ter] and c.1227-2A>G). Truncating variants in MYBPC3 are known to lead to severe, early-onset disease when expressed in homozygosity <sup>31</sup>. The patient carrying the 332 333 nonsense variant p.Glu520Ter was indeed diagnosed with HCM at birth and died suddenly 334 before adolescence. In contrast, the patient carrying the c.1227-2A>G splice variant in 335 homozygosity presented with HCM in adulthood, although at a younger age and with more 336 severe hypertrophy (LVMWT: 27mm vs. 20mm) than the patient with the same variant in the 337 heterozygous state. Accordingly, this splice acceptor variant is predicted (by SpliceAI) to result 338 in an exon extension of 33 intronic bases into the MYBPC3 transcript, which suggests that the 339 variant maintains the open reading frame and may therefore function as an inframe insertion 340 (Supplementary Figure 2).

341

342 Notably, homozygous variants were particularly enriched in three minor HCM genes (i.e. those 343 previously shown to account for less than 5% of HCM patients each in European populations) - CSRP3 and the MLC genes MYL2 and MYL3<sup>18</sup> (Table 3). Therefore, we sought to compare 344 345 the relative contribution of homozygous variants across the HCM genes. The proportion of 346 rare homozygous variants was consistent across the major HCM genes, with 5-7% of variants 347 being homozygous in MYH7, MYBPC3 and the thin filament genes (Table 4 and Figure 2). 348 This proportion could be regarded as a background homozygosity rate for dominant HCM 349 genes caused by the level of consanguinity present in the Egyptian population. In contrast the MLC and CSRP3 genes showed a substantially higher proportion of homozygous variants 350 351 (25.6% and 33.3%, respectively). It is worth mentioning that the increase in frequency of MLC 352 homozygous variants from 14.3% (using the rare frequency threshold) to 25.6% (using the 353 biallelic frequency threshold) was largely due to a recurrently observed low-frequency

354 (gnomAD<sub>popmax</sub> FAF=4.4x10<sup>-5</sup>) *MYL3* variant c.530A>G [p.Glu177Gly] in the Egyptian cohort 355 (0.78%,n=4).

356

357 These findings suggest that, unlike the major HCM genes, rare variants in these minor genes 358 may be generally less penetrant in the heterozygous state. Evidence for an additive, rather 359 than a true recessive, model is supported by the fact that heterozygous variants in these genes 360 are also enriched in Egyptian patients compared to controls and that the vast majority of 361 previously reported pathogenic CSRP3 and missense MLC variants have been associated 362 with autosomal dominant HCM. Taken together, these findings explain the relatively higher proportion of rare variants in MLC and CSRP3 genes observed in Egyptian patients compared 363 364 to UK (Figure 1), with high consanguinity rates enabling variants to occur in a more penetrant 365 homozygous state.

Gene	Variant type	cDNA variant	Protein variant	gnomAD FAF <sub>popmax</sub>	Control hom freq (count)	Control het freq (count)	HCM hom case freq (count)	HCM het case freq (count)
A) Sufficier	ntly rare variants (	gnomAD FAF <sub>popmax</sub> ≤	0.00126) to cause mor	no allelic HCM			•	
МҮН7	Missense	c.5122G>A	p.Glu1708Lys	0	0%	0%	0.19% (1)	0%
	Missense	c.4258C>T	p.Arg1420Trp	3.0x10 <sup>-6</sup>	0%	0%	0.19% (1)	0.39% (2)
	Missense	c.3622G>C	p.Asp1208His	0	0%	0%	0.19% (1)	0.58% (3)
	Missense	c.1064C>T	p.Ala355Val	0	0%	0%	0.19% (1)	0%
	Missense	c.925G>A	p.Asp309Asn	1.1x10⁻⁵	0%	0%	0.19% (1)	0.78% (4)
	Frameshift*	c.5769delG	p.Ser1924AlafsTer9	0	0%	0%	0.19% (1)	3.11% (16)
	Missense	c.2908C>T	p.Arg970Trp	0	0%	0.25% (1)	0.19% (1)	0.39% (2)
	Missense	c.2458C>G	p.Arg820Gly	0	0%	0%	0.19% (1)	0%
МҮВРС3	Inframe Deletion	c.2441_2443delA GA	p.Lys814del	0	0%	0%	0.19% (1)	0%
	Nonsense	c.1558G>T	p.Glu520Ter	0	0%	0%	0.19% (1)	0%
	Splice acceptor	c.1227-2A>G	-	0	0%	0%	0.19% (1)	0.19% (1)
MYL2	Missense	c.278C>T	p.Ala93Val	0	0%	0%	0.19% (1)	0.78% (4)
MYL3	Missense	c.508G>C	p.Glu170Gln	0	0%	0%	0.58% (3)	0.58% (3)
TNNI3	Missense	c.485G>T	p.Arg162Leu	0	0%	0%	0.19% (1)	0%
	Splice acceptor	c.415-1G>C	-	0	0%	0%	0.19% (1)	0%
CSRP3	Splice donor	c.414+1G>T	-	0	0%	0.25% (1)	0.58% (3)	0.19% (1)
	Missense	c.365G>A	p.Arg122GIn	2.9x10 <sup>-6</sup>	0%	0%	0.19% (1)	0.58% (3)
B) Sufficier	ntly rare variants (	gnomAD FAF <sub>popmax</sub> ≤	0.00126) to cause bial	lelic HCM				
МҮВРС3	Missense	c.3676C>T	p.Arg1226Cys	6.4x10 <sup>-5</sup>	0%	0%	0.19% (1)	0%
	Missense	c.2618C>A	p.Pro873His	9.3x10⁻⁵	0%	0%	0.19% (1)	0%
	Missense	c.1321G>A	p.Glu441Lys	2.0x10 <sup>-4</sup>	0%	2.0% (8)	0.39% (2)	4.3% (22)
MYL3	Missense	c.530A>G	p.Glu177Gly	4.4x10⁻⁵	0%	0.75% (3)	0.78% (4)	0.19% (1)
	Missense	c.170C>A	p.Ala57Asp	4.0x10 <sup>-4</sup>	0%	0%	0.39% (2)	0.19% (1)
JPH2	Missense	c.572C>G	p.Pro191Arg <sup>‡</sup>	2.0x10 <sup>-4</sup>	0%	0.25% (1)	0.19% (1)	0.19% (1)

# 366 Table 3: Details of homozygous variants identified in the Egypt HCM cohort (n=514) compared to Egypt controls (n=400)

A) Summary of Egyptian variants that are sufficiently rare (gnomAD FAF<sub>popmax</sub> $\leq$ 4x10<sup>-5</sup>) to cause mono allelic disease. B) Additional variants that are sufficiently rare (gnomAD FAF<sub>popmax</sub> $\leq$ 0.00126) to cause biallelic disease are also shown. \*The *MYH7* variant c.5769delG was caused by a nucleotide deletion that was predicted to ultimately give rise to a near full-length protein (i.e., only 4 AAs shorter than the wildtype). The control frequency represents heterozygous counts (no homozygous variants were identified). <sup>‡</sup>This variant is unlikely to be pathogenic as it co-occurred with the pathogenic *MYH7* variant p.Arg870His in the HCM patient (also, it's allele frequency in gnomAD-Ashkenazi Jewish population is 0.007215).

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

## 367

368

# Table 4: Relative contribution of homozygous variants for validated autosomal dominant HCM genes


	Variants with gnomAD FAF <sub>popmax</sub> ≤4x10 <sup>-5</sup>		Additional v gnomAD FAF <sub>p</sub>	Total hom	
Gene/Gene groups	Total no. of patients	Hom case freq(count)	Total no. of patients	Hom case freq(count)	freq (count/total)
MYH7	99	6.1% (6)	5	0%	5.8% (6/104)
MYBPC3	85	5.9% (5)	45	8.9% (4)	6.9% (9/130)
CSRP3	15	33.3% (5)	0	0%	33.3% (5/15)
Myosin light chain	28	14.3% (4)	11	54.5% (6)	25.6% (10/39)
Thin filament	18	5.6% (1)	8	0%	3.8% (1/26)
ACTN2	12	0%	8	0%	0% (0/20)
JPH2	14	0%	4	25% (1)	5.6% (1/18)
PLN	0	0%	0	0%	0%

For genes with an excess burden of rare variants in Egypt HCM patients vs. UK (Table 2). The relative
 contribution of rare (gnomAD FAF<sub>popmax</sub>≤4x10<sup>-5</sup>) homozygous variants under dominant HCM model (left)
 as well as of additional variants under recessive inheritance model (gnomAD FAF<sub>popmax</sub>≤0.00126) (right)

are shown. MLC: *MYL2*, *MYL3*. Thin filament: *ACTC1*, *TNNC1*, *TNNI3*, *TNNT2*, *TPM1*. 375

376

377



# 378 Figure 2: Comparison of the rate of homozygosity across the analyzed dominant HCM genes.

379 MLC- (*MYL2*, *MYL3*) and *CSRP3* genes showed a markedly higher rate of homozygosity compared to 380 major HCM genes (*MYBPC3*, *MYH7*) and thin filament genes (*ACTC1*, *TNNC1*, *TNNI3*, *TNNT2*, *TPM1*).

# 381 A significantly higher proportion of VUSs is observed in the Egypt HCM cohort 382 compared to UK HCM

In contrast to MENA populations, European HCM patients have been extensively studied over the past decades. As a result, they are more likely to carry a disease-causing variant that has been previously well-characterized. Therefore, we hypothesize that in patients with rare variants in validated HCM genes, Egyptians have a higher proportion of VUSs compared to the UK HCM cohort.

388

The proportion of patients with rare variants in HCM genes was 46.7% (n=240) and 28.9% (n=198) in the Egypt and UK HCM cohorts, respectively. As expected, the proportion of VUSs was significantly higher in the Egypt HCM cohort compared to UK (59.2% vs. 38.4%, pvalue= $1.6 \times 10^{-5}$ ), which highlights the challenge in interpreting variants in understudied populations (Figure 3).

394




Figure 3: Higher proportion of Variants of Uncertain Significance (VUSs) is observed in (A) Egyptian patients compared to (B) UK. For patients with rare variants in validated HCM genes, the distribution of rare variants by variant classification (pathogenic (P), Likely Pathogenic (LP) and VUSs) is shown. For patients with multiple hits (Supplementary Tables 6 and 7) the variant with the highest pathogenicity was prioritized (i.e., P then LP then VUS). The proportion of VUSs was significantly higher in Egypt HCM patients vs. UK (59.2% vs. 38.4%, p-value=1.6x10<sup>-5</sup>).

402

## 403 Analysis of HCM rare variation in the ancestry-matched Egyptian case-control cohort 404 increases the proportion of clinically actionable variants

405 The availability of genetic data from a deeply-phenotyped control cohort of 400 Egyptians as 406 well as cohort-level analysis of the HCM patients described here enabled us to re-evaluate 407 the classification of identified VUSs in patients by adopting 3 approaches. First, we examined 408 whether these VUSs were prevalent among our control cohort (i.e.  $n \ge 2$ ; MAF $\ge 0.0025$ ), which 409 would increase the likelihood of them being likely benign. Then, we assessed if a subset of 410 these VUSs could be reclassified to LP based on their enrichment in Egyptian patients (ACMG/AMP PS4 rule) or whether they reside in a previously defined mutational hotspot 411 412 region that has been reported to be enriched for HCM-associated variation (modified 413 ACMG/AMP PM1 rule)<sup>13,32</sup>.

414

415 Our analysis showed that 1 VUS (MYBPC3 c.305C>T [p.Pro102Leu]) was observed in two 416 Egyptian controls and thus could be reclassified to likely benign according to the ACMG/AMP 417 rules BS1 and BP4<sup>29</sup>. It is worth mentioning that here variant rarity was defined using 418 gnomAD, which lacks sufficient data from MENA populations. Given that variant frequencies 419 may differ across diverse ancestral populations, it is not unexpected to observe "rare" variants 420 in gnomAD to be more prevalent in Egypt (more details in Supplementary Figure 1).

421

422 We then adopted the modified ACMG/AMP PS4 rule proposed by ClinGen, whereby variants 423 prevalent among at least 2, 6 or 15 patients could activate the PS4- supporting, moderate and strong rules, respectively <sup>32</sup>. The PS4 evidence strength levels associated with these specific 424 425 patient counts were based on likelihood ratios with ideal target thresholds set by ClinGen of 426 10 (PS4-supporting), 30 (moderate) and 100 (strong), respectively <sup>32</sup>. Of all rare variants 427 identified in Egypt HCM patients, irrespective of variant classification, 48,3 and 1 distinct variant(s) were recurrently found in  $n \ge 2$ ,  $n \ge 6$  and  $n \ge 15$  patients, respectively. Application 428

429 of the modified PS4 rule upgraded the classification of 6/104 VUSs to LP (5.8%) and 10/30
430 LP variants to P (33.3%).

431

432 We previously identified specific regions in sarcomeric genes in which rare non-truncating 433 variants were significantly enriched in >6,000 HCM patients of predominantly Europeanancestry (LMM/OMGL) compared to controls <sup>21</sup>. For variants residing in these case-enriched 434 435 clusters, the etiological fraction (EF) was calculated as it provides a quantitative estimate of 436 the probability that a rare non-truncating variant identified in an individual with HCM is disease-437 causing. Based on the EF findings, the authors proposed an adaptation to the ACMG/AMP 438 guidelines whereby rare variants located in an HCM cluster with an EF>0.95 could activate 439 the PM1 hotspot rule at a modified strong evidence level (leading to the re-classification of 440 VUS to LP).

441

442 As the relative case-control frequencies can differ across population groups, similar 443 enrichment needs to be demonstrated in the population of interest before adopting these 444 modified guidelines. Given the abundance of rare non-truncating variants observed in MYH7 445 in the Egypt HCM cohort, we sought to validate the EF-based PM1 ACMG/AMP rule for MYH7 446 variants (there were insufficient variants to accurately assess clustering in the troponin genes). 447 First, we examined whether the distribution and enrichment of MYH7 non-truncating variants 448 was similar between the Egypt and the LMM/OMGL (n=6,112) HCM datasets. As depicted in 449 Figure 4A, a similar distribution of rare missense MYH7 variants was observed between 450 Egyptian and LMM/OMGL HCM patients, with rare variants in the pre-defined HCM cluster 451 (residues 167-931) significantly enriched in the Egypt HCM cohort over Egypt controls (13.04% vs. 0.25%, p-value=2.2x10<sup>-16</sup>). As the EF for Egyptian variants within the pre-defined 452 453 HCM cluster was 1.0 (95%CI: 0.93-1.0), we applied the EF-based PM1 strong ACMG/AMP 454 on rare Egyptian MYH7 missense variants, irrespective of prior variant classification. A total of 48 missense MYH7 variants were identified in the Egypt HCM cohort (Supplementary Table 455 456 2). Application of the EF-based PM1 strong rule upgraded the classification of 23 VUSs to LP

457 and three LP variants to P, which increased the overall proportion of clinically actionable (i.e.


458 P/LP) distinct *MYH7* missense variants from 35.4% to 83.3%.

459

Taken together, applying the above-mentioned approaches to variant interpretation increased the overall proportion of Egypt HCM patients with clinically actionable variants from 19% to 33.4% (relative increase from 40.8% to 60.4% in the patient subgroup with rare variants in validated HCM genes) (Figure 4B).



# Α



466 467

Figure 4: A) Similar enrichment of rare, missense MYH7 variants between the Eqypt- and large-468 scale HCM cohort of predominantly European ancestry (LMM/OMGL n=6,112) in the predefined 469 HCM cluster (red) (residues 167-931). Rare variants in the HCM cluster were enriched in the Egypt 470 HCM cohort over Egypt controls with an Etiological Fraction (EF) of 1.0. B) Application of ClinGen's 471 modified ACMG/AMP PS4 rule and Walsh et al., 2019 proposed EF-based PM1 strong rules in 472 the Egyptian case-control cohort increases the proportion of Egypt HCM patients with clinically 473 actionable variants from 19% to 33.4%. Rare variants were initially classified based on the 474 ACMG/AMP guidelines (initial analysis) and then reclassified after integrating ancestry-matched 475 controls into the analysis (cohort-informed analysis) and adopting Egypt-specific PS4 and the modified 476 EF-based PM1 strong rules. Cohort-informed analysis revealed that MYBPC3 p.Pro102Leu was 477 prevalent in the Egypt control cohort (MAF=0.0025) and thus was reclassified from VUS (in case-level 478 analysis) to likely benign (LB, activated ACMG/AMP rules: BS1&BP4). P: pathogenic, LP: likely 479 pathogenic, VUS: variant of uncertain significance.

- 480
- 481

#### 482 Enrichment of non-rare variants in Egypt HCM patients

483 A growing body of evidence suggests that low frequency variants could contribute to disease risk with intermediate effects <sup>33</sup>. These variants can be identified through burden tests showing 484 485 an enrichment in patients followed by functional analyses to investigate their effect on the 486 disease phenotype. Therefore, we sought to assess if low-frequency variants (i.e.  $4x10^{-5}$ 487 gnomAD FAF<sub>popmax</sub>< 0.01) were enriched in the Egypt HCM cohort compared to Egypt 488 controls. A total of 20 non-rare protein-altering variants in validated HCM genes were 489 observed in more than one patient in the Egypt HCM cohort (Supplementary Table 10). Of these, MYBPC3 c.1321G>A [p.Glu441Lys] and TNNT2 c.832C>T [p.Arg278Cys] were 490 nominally enriched in Egyptian patients over controls (4.67% vs. 2%, p-value=0.03, OR=2.4 491 492 (95%CI: 1.0-6.2) and 1.17% vs. 0%, p-value=0.04, OR=10.2 (95%CI: 0.6-182.3), respectively) 493 (although not statistically significant after multiple testing correction). While p.Arg278Cvs is 494 enriched in HCM in both Egyptian and European-ancestry cohorts, including the analyzed UK 495 cohort, p.Glu441Lys is infrequently observed in most European HCM cohorts (Supplementary Table 11) <sup>34–37</sup>. This suggests that this variant could be more relevant to Middle Eastern 496 497 populations. Several publications reported the frequent co-occurrence of these variants with other sarcomeric variants suggesting that they may act as disease modifiers<sup>33,38–41</sup>. Notably, 498 499 37.5% (n=9/24) and 33.3% (n=2) of Egyptian patients with p.Glu441Lys and p.Arg278Cys, 500 respectively, carried another rare sarcomeric variant, including two patients who carried 501 p.Glu441Lys in homozygosity (Supplementary Table 11).

502

### 503 Higher prevalence of *TRIM63* biallelic variants in the Egypt HCM cohort compared to 504 Europeans

505 Salazar-Mendiguchía et al., 2020 have recently proposed that TRIM63 is a recessive HCM 506 gene associated with concentric LVH and a high rate of LV dysfunction following the 507 identification of homozygous or compound heterozygous variants in 0.4% of a predominantly European (>90%) HCM cohort <sup>42</sup>. We identified seven homozygous and one compound 508 509 heterozygous TRIM63 variants in the Egypt HCM cohort (total=8/374, 2.14%) (Supplementary

510 Table 9). No biallelic *TRIM63* variants were identified in the Egypt control cohort. Similar to 511 the recent study, c.224G>A [p.Cys75Tyr] (1.34%) and c.739C>T [p.Gln247Ter] (0.53%) (both 512 homozygous) were the most frequently identified TRIM63 biallelic variants in the Egypt HCM 513 cohort<sup>42</sup>. The missense variant Cys75Tyr was observed in heterozygosity in 0.5% (2/400) of 514 the Egypt control cohort and in two individuals from the North African sub-populations from 515 the GME study (in hetero- and homozygosity), which indicates that this variant could be particularly prevalent in North African/MENA populations <sup>43</sup>. A markedly higher frequency of 516 517 biallelic TRIM63 variants was observed in the Egypt HCM cohort compared to both the analyzed UK HCM cohort and the recently published European-ancestry enriched cohort 518 (2.14%% vs 0.16%, p-value=0.0019 and vs. 0.4%, p-value=5.8x10<sup>-5</sup>, respectively) <sup>42</sup>. 519

520

# 521 Discussion

This study represents the largest and most comprehensive analysis of HCM in the MENA region to date. Here, we report the results of genetic analysis of 514 unrelated Egyptian HCM patients and 400 ancestry-matched controls. We show that cohort-level analysis of rare variation in the hitherto understudied Egyptian population provides accurate interpretation of variants rarely observed in published HCM patient groups. In addition, we demonstrate that studying consanguineous populations allows for distinguishing between the relative pathogenicity and penetrance of disease-causing genes.

529

530 First, we show that the proportion of patients with rare variants in validated HCM genes was 531 higher in the Egypt HCM cohort compared to UK HCM (52.7% vs. 32.0%). Recent data from 532 ShaRe registry demonstrated that patients carrying sarcomere variants presented with HCM 533 at an earlier age and had a worse prognosis <sup>10</sup>. Here, Egyptian patients presented with a 534 higher yield of sarcomeric variants compared to the UK HCM cohort (44.8% vs. 29.5%).

535

Patients analyzed here were admitted to AHC, which is a tertiary referral center. Thus, they typically presented with severe clinical manifestations at admission. This may explain the markedly younger age of onset (by ca. 20 years) and more severe LVH observed in the Egypt HCM cohort compared to UK HCM. To account for a possible referral bias, we compared the proportion of genotype positive patients attributable to each gene between the Egypt and UK HCM cohorts.

542

MYBPC3 and MYH7 accounted for the majority of rare variation, as with all HCM cohorts. 543 544 However, some key differences are observed between the Eqypt HCM and UK HCM cohorts. 545 For example, we have recently reported the identification of a new class of pathogenic variants 546 in HCM; a nonsense mediated decay-incompetent frameshift variant (c.5769delG) in MYH7, 547 which was recurrently observed in Egyptian patients (3.3%) and absent from large-scale (n>6,000) HCM patients of predominantly European ancestry <sup>16,18</sup>. Also, the Egypt HCM data 548 549 shows an enrichment of JPH2 missense variants (5.2% Egypt HCM vs. 1.4% UK HCM 550 genotype-positive patients) which rarely cause HCM outside of founder populations. This is 551 largely explained by two recurrent variants that have not been previously reported <sup>25</sup>. One of 552 these variants, p.Thr161Ala, occurs at the same position as another pathogenic variant (p.Thr161Lys) recently reported to be a founder in the Finnish population <sup>44</sup>. This may denote 553 554 a particular pathogenic hotspot in JPH2 although further segregation and/or functional data 555 are required to enable a more accurate classification of these variants.

556

The main unique finding, however, relates to the clear prevalence of HCM minor genes, particularly *MYL2*, *MYL3* (MLC) and *CSRP3*, in the Egyptian population and the enrichment of homozygous variants in these genes. A noticeably higher proportion of rare variants in MLC genes was observed in the genotype-positive Egypt HCM cohort compared to UK HCM (10.33% vs. 2.28%), including five recurrent variants that were absent from the latter cohort. Interestingly, a substantial proportion of MLC variants (25.6%) were observed in the homozygous state, suggesting such variants are less penetrant in heterozygosity. In

564 agreement with this notion, a study by Claes et al., 2016 demonstrated that the expression of 565 the Dutch founder MYL2 missense variant p.Glu22Lys in isolation was associated with low HCM penetrance and a benign disease manifestation and that the presence of an additional 566 567 risk factor, including hypertension, obesity or the co-occurrence of another sarcomeric variant, 568 increased the disease penetrance from 36% to 89% in *MYL2*-variant carriers <sup>45</sup>. In addition, 569 the authors reported that patients carrying p.Glu22Lys in homozygosity were diagnosed with end-stage heart failure due to HCM in their 30s<sup>45</sup>. It is therefore plausible to conclude that the 570 571 high consanguinity rates observed in the Egypt HCM cohort enabled MLC variants to occur in 572 a more penetrant homozygous state. This may explain, at least in part, the relatively higher proportion of rare MLC variants observed in the analyzed consanguineous Egypt HCM cohort 573 574 compared to UK HCM. While biallelic truncating variants in MYL2/MYL3 are associated with 575 severe early onset cardioskeletal myopathies, only two homozygous missense variants in MYL3 have previously been reported - p.Glu143Lys<sup>46,47</sup> and p.Ala57Asp<sup>48,49</sup>. It is 576 577 noteworthy that the homozygous expression of the non-rare variant p.Ala57Asp, which was observed in HCM patients of Iranian and Tunisian origins born to consanguineous parents<sup>48,49</sup>, 578 579 was also observed in the Egypt HCM cohort (in two homozygous and one heterozygous 580 carriers). The homozygous patients presented with HCM at a relatively younger age and had 581 a greater LVWMT (27+2.8mm vs. 16mm) compared to the heterozygous carrier. Although a 582 previous functional study with iPSC-CMs did not demonstrate a phenotype for this variant in 583 either the heterozygous or homozygous state<sup>50</sup>, the fact that is has now been detected as a 584 homozygous variant in four HCM cases (and not detected in our healthy control cohort) 585 suggests it is contributing to the phenotype.

586

587 Similar to MLC-encoding genes, variants in *CSRP3* were more likely to present in 588 homozygosity (33.3%) than the major sarcomere-encoding HCM genes (*MYH7*, *MYBPC3* and 589 thin filament genes, 5-7%). Two of the three homozygous *CSRP3* variants were truncating 590 (c.415-1G>C and c.414+1G>T). These variants were observed in one and three Egyptian 591 patients, respectively. Patients carrying these variants presented with HCM at an average age

of 45.5+8.7 and a LVMWT of 16.5+2.4mm. It is noteworthy that c.414+1G>T was also 592 593 observed in heterozygosity in one Egyptian control and HCM patient, respectively. The control did not carry any other rare HCM-associated variant whereas the HCM patient carried the 594 595 pathogenic MYH7 c.5769delG variant (and the JPH2 p.Ser99Asn VUS), suggesting that in the 596 heterozygous state this variant requires an additional mutational burden to express the HCM 597 phenotype. To date, only three knockout CSRP3 HCM patients have been reported in Poland and France, two of whom were confirmed to be born to consanguineous parents<sup>51,52</sup>. These 598 599 patients were diagnosed with adult-onset HCM and one patient underwent Implantable cardioverter defibrillator implantation in her 30s<sup>51,52</sup>. Together, these studies suggest that full 600 601 CSRP3 gene knockouts, in contrast to the severe early-onset phenotypes observed with 602 biallelic truncating variants in genes like MYBPC3 and ALPK3, are associated with more 603 typical adult-onset HCM, despite the fact that most reports for CSRP3-associated HCM 604 involve heterozygous variants and dominant inheritance.

605

606 Taken together, these findings demonstrate that this study is uniquely able to examine the 607 frequency of homozygous variants in dominant HCM genes using a large consanguineous 608 cohort to inform the relative penetrance of variants in these genes. The recurrence of these 609 variants in the Egyptian cohort, which may indeed have generally higher prevalence in other 610 consanguineous populations of the MENA region, exemplifies the need to integrate new 611 guidelines tailored to the classification of homozygous variants into the current ACMG 612 framework in order to enhance the utility of clinical genetic testing in other consanguineous 613 populations.

614

The observed high prevalence of consanguinity (28%) in the Egyptian cohort analyzed here has also enabled us to validate recent findings reporting the association of the recessive gene *TRIM63* to HCM <sup>42</sup>. Indeed, the prevalence of biallelic *TRIM63* variants was markedly higher in Egyptian patients compared to HCM patients of European ancestries suggesting that

619 recessive inheritance patterns of HCM are more likely to occur in consanguineous populations620 of the MENA region.

621

622 Our data also highlight the value of performing ancestry-matched case-control analysis 623 coupled with standardized guidelines and guantitative approaches to variant interpretation to accurately classify variants observed in underrepresented populations <sup>13,29,32</sup>. We demonstrate 624 625 that these approaches enabled 23.1% of distinct VUSs identified in the Egypt HCM cohort to 626 progress to likely pathogenic, enabling a more equitable application of clinical genetic testing 627 in the region. Expanding the MENA dataset in resources like gnomAD will further improve the 628 interpretation of VUSs by providing more accurate frequencies of these variants in the 629 population.

630

631 It is noteworthy that despite the relatively severe phenotypes observed in our cohort, almost 632 50% of HCM patients in this study presented with an unexplained genetic etiology. This finding 633 is not unexpected as recent evidence suggests that the genetic etiology of HCM is more 634 complex and that common variants with individually small (but collectively large) effect sizes could explain some of the missing heritability of the disease <sup>53,54</sup>. This study is not designed 635 636 to assess common variants or validate recently described European-ancestry HCM polygenic risk scores (PRS)<sup>54</sup>. However, a recent HCM genome-wide association study (GWAS) 637 638 identified a common BAG3 missense variant p.Cys151Arg, as one of the two most strongly 639 associated loci for HCM and which is covered by the targeted gene panel used in this 640 analysis<sup>54</sup>. The OR of p.Cys151Arg was highly similar between the Egyptian cohorts and the 641 published European datasets, 1.47 (95%CI: 1.12-1.95) and 1.42 (95%CI: 1.29-1.55) 642 respectively <sup>54</sup>, although the population frequency for the minor risk allele is lower in Egypt 643 (control MAF=0.12) than Europe (gnomAD-non-Finnish European MAF=0.22). This suggests 644 that there will be likely many shared loci between populations, although well-powered GWAS 645 in MENA populations are warranted to accurately quantify HCM PRS for future clinical use.

646

647 Low frequency variants with effect sizes that are intermediate between common GWASderived and rare Mendelian variants are now also emerging as additional genetic risk factors. 648 649 For example, a recent study by Pua et al. identified two low frequency troponin variants (TNN/3 650 p.Arg79Cys OR=3.3 (96%CI: 1.5-7.2), MAF=0.018 and TNNT2 p.Arg286His OR=14.1 651 (95%CI: 6.0-33.0), MAF=0.022) that are associated with HCM in patients of Chinese ancestry 652 <sup>55</sup>. Similarly, we observed two low frequency variants *MYBPC3* p.Glu441Lys (OR=2.4 (95%CI: 653 1.0-6.2), MAF=0.025) and TNNT2 p.Arg278Cys (OR= 10.2 (95%CI: 0.6-182.3), MAF=0.006) 654 that were nominally enriched in the Egyptian HCM cohort. While the TNNT2 p.Arg278Cys 655 variant is also consistently enriched in European ancestry cohorts, the MYBPC3 variant 656 p.Glu441Lys is clearly more prevalent in the Egypt HCM cohort, suggesting that it could be more relevant to Egyptian patients <sup>34–37</sup>. In agreement with literature findings, both variants 657 658 were frequently observed in conjunction with another sarcomeric variant in Egyptian patients, which suggests their modifier effect on the phenotype <sup>38–41</sup>. However, functional studies will 659 660 be required to definitively ascertain their effect on HCM phenotype.

661

A limitation of the study is that the targeted gene panel used does not include genes that have been recently shown to be associated with HCM (*ALPK3*, *FHOD3* and *FLNC*<sup>56–59</sup>). In addition, the study design did not account for common and copy number variations, non-coding variants or epigenetic factors, which may contribute to HCM pathogenesis. Finally, larger control datasets are needed to fully characterize rare variation in MENA populations.

667

In conclusion, we have demonstrated that detailed analysis of rare genetic variation in validated HCM genes in underrepresented populations reveals novel findings with relevance to both clinical genetic testing and our understanding of the genetic etiology of HCM. We report the contribution of minor HCM genes, rarely observed in outbred populations, to disease pathogenicity. We also show a higher prevalence of biallelic variants in the recessive HCM gene *TRIM63* in Egyptian patients suggesting that recessive inheritance of HCM is more likely to occur in consanguineous populations. These unique genetic features exemplify the value

of studying diverse ancestral populations. The highly consanguineous cohort analyzed here
opens new research avenues for the discovery of novel recessive genes in future exome or
genome sequencing studies.

678

# 679 Acknowledgements

We would like to acknowledge Dr. Rafik Tadros and Dr. Paloma Jordà for providing us with
HCM and control frequency data regarding the recently reported *BAG3* variant p.Cys151Arg.
We would like to thank the AHC nursing staff and team members who contributed to the
biobanking efforts in frame of the National HCM Registry.

684

# 685 Funding Statement

686 This study is part of the Egyptian Collaborative Cardiac Genomics Project. It was supported 687 by the Science and Technology Development Fund government grant (Egypt), the Wellcome 688 Trust (107469/Z/15/Z; 200990/A/16/Z), the Medical Research Council (United Kingdom), the 689 NIHR Royal Brompton Cardiovascular Biomedical Research Unit, the NIHR Imperial College 690 Biomedical Research Center, and a Health Innovation Challenge Fund award from the 691 Wellcome Trust\* and Department of Health, United Kingdom (HICF-R6-373)\*\*. Drs Allouba 692 and Halawa were funded by Al Alfi Foundation to support their PhD degrees at Imperial 693 College London and American University in Cairo, respectively. Dr Aguib is supported by 694 Fondation Leducg (11 CVD-01).

\*This research was funded in part by the Wellcome Trust [107469/Z/15/Z]. For the purpose of
open access, the author has applied a CC BY public copyright licence to any Author Accepted
Manuscript version arising from this submission.

698 \*\*The views expressed in this work are those of the authors and not necessarily those of the699 funders.

700

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

# 702 Web resources

703 OMIM, https://www.omim.org

704

705

711

712

713

720

721 722

723

724

725

726

727

728

734

735 736

737

738 739

740

741

742 743

744

745

# 706 **References**

- Maron, B. J., Gardin, J. M., Flack, J. M., Gidding, S. S., Kurosaki, T. T., & Bild, D. E. (1995). Prevalence of hypertrophic cardiomyopathy in a general population of young adults: Echocardiographic analysis of 4111 subjects in the CARDIA study. *Circulation*, 92(4), 785–789. https://doi.org/10.1161/01.CIR.92.4.785
  - 2. Semsarian, C., Ingles, J., Maron, M. S., & Maron, B. J. (2015). New perspectives on the prevalence of hypertrophic cardiomyopathy. In *Journal of the American College of Cardiology* (Vol. 65, Issue 12). https://doi.org/10.1016/j.jacc.2015.01.019
- 714 3. Teare, D. (1958). Asymmetrical hypertrophy of the heart. *British Heart Journal*, 20(1), 1–8.
- Maron, M. S., & Maron, B. J. (2015). Clinical impact of contemporary cardiovascular magnetic resonance imaging in hypertrophic cardiomyopathy. *Circulation*, *132*(4). https://doi.org/10.1161/CIRCULATIONAHA.114.014283
   Maron, B. J., Ommen, S. R., Semsarian, C., Spirito, P., Olivotto, I., & Maron, M. S.
  - Maron, B. J., Ommen, S. R., Semsarian, C., Spirito, P., Olivotto, I., & Maron, M. S. (2014). Hypertrophic cardiomyopathy: Present and future, with translation into contemporary cardiovascular medicine. In *Journal of the American College of Cardiology* (Vol. 64, Issue 1). <u>https://doi.org/10.1016/j.jacc.2014.05.003</u>
    - Maron, B. J., Rowin, E. J., Casey, S. A., & Maron, M. S. (2016). How Hypertrophic Cardiomyopathy Became a Contemporary Treatable Genetic Disease With Low Mortality. *JAMA Cardiology*, 1(1). https://doi.org/10.1001/jamacardio.2015.0354
  - Marian, A. J., & Braunwald, E. (2017). Hypertrophic cardiomyopathy: Genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. *Circulation Research*, 121(7), 749–770. <u>https://doi.org/10.1161/CIRCRESAHA.117.311059</u>
- 8. Lu, D. Y., Pozios, I., Haileselassie, B., Ventoulis, I., Liu, H., Sorensen, L. L., Canepa, 729 730 M., Phillip, S., Roselle Abraham, M., & Abraham, T. P. (2018). Clinical outcomes in 731 patients with nonobstructive, labile, and obstructive hypertrophic cardiomyopathy. 732 Journal of the American Heart Association, 7(5). 733 https://doi.org/10.1161/JAHA.117.006657
  - O'Mahony, C., Jichi, F., Ommen, S. R., Christiaans, I., Arbustini, E., Garcia-Pavia, P., Cecchi, F., Olivotto, I., Kitaoka, H., Gotsman, I., et al. (2018). International external validation study of the 2014 European society of cardiology guidelines on sudden cardiac death prevention in hypertrophic cardiomyopathy (EVIDENCE-HCM). *Circulation*, 137(10). <u>https://doi.org/10.1161/CIRCULATIONAHA.117.030437</u>
  - Ho, C. Y., Day, S. M., Ashley, E. A., Michels, M., Pereira, A. C., Jacoby, D., Cirino, A. L., Fox, J. C., Lakdawala, N. K., Ware, J. S., et al. (2018). Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy. *Circulation*, *138*(14), 1387–1398. <u>https://doi.org/10.1161/CIRCULATIONAHA.117.033200</u>
  - 11. Elliott, P. (2018). Hypertrophic cardiomyopathy lifelong disease requiring lifelong treatment. In *Circulation* (Vol. 138, Issue 14). https://doi.org/10.1161/CIRCULATIONAHA.118.035932
- 12. Olivotto, I., Oreziak, A., Barriales-Villa, R., Abraham, T. P., Masri, A., Garcia-Pavia, P.,
  Saberi, S., Lakdawala, N. K., Wheeler, M. T., Owens, A., et al. (2020). Mavacamten
  for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORERHCM): a randomised, double-blind, placebo-controlled, phase 3 trial. *The Lancet*,
  396(10253). https://doi.org/10.1016/S0140-6736(20)31792-X
- 13. Walsh, R., Mazzarotto, F., Whiffin, N., Buchan, R., Midwinter, W., Wilk, A., Li, N.,
  Felkin, L., Ingold, N., Govind, R., et al. (2019). Quantitative approaches to variant

760

761

762

763

764

765

766

767 768

769

770

771

772

773

774

775

776

777 778

779

780

781

782

783

784 785

786 787

788

789

790

791

792

793

794

795

796

797

798

799

800

801

753

754

classification increase the yield and precision of genetic testing in Mendelian diseases : the case of hypertrophic cardiomyopathy. *Genome Medicine*, *11*(5), 1–18.
14. Dellefave-Castillo, L. M., Cirino, A. L., Callis, T. E., Esplin, E. D., Garcia, J., Hatchell,

- Dellefave-Castillo, L. M., Cirino, A. L., Callis, T. E., Esplin, E. D., Garcia, J., Hatchell, K. E., Johnson, B., Morales, A., Regalado, E., Rojahn, S., et al. (2022). Assessment of the Diagnostic Yield of Combined Cardiomyopathy and Arrhythmia Genetic Testing. *JAMA Cardiology*. https://doi.org/10.1001/jamacardio.2022.2455
- Landry, L. G., & Rehm, H. L. (2018). Association of racial/ethnic categories with the ability of genetic tests to detect a cause of cardiomyopathy. *JAMA Cardiology*, 3(4), 341–345. https://doi.org/10.1001/jamacardio.2017.5333
  - 16. Aguib, Y., Allouba, M., Walsh, R., Ibrahim, A. M., Halawa, S., Afify, A., Hosny, M., Theotokis, P. I., Galal, A., Elshorbagy, S., et al. (2021). New Variant with a Previously Unrecognized Mechanism of Pathogenicity in Hypertrophic Cardiomyopathy. *Circulation*, 144(9), 754–757. https://doi.org/10.1161/CIRCULATIONAHA.120.048295
    - 17. Aguib, Y., Allouba, M., Afify, A., Halawa, S., El-Khatib, M., Sous, M., Galal, A., Abdelrahman, E., Shehata, N., el Sawy, et al. (2020). The Egyptian Collaborative Cardiac Genomics (ECCO-GEN) Project: defining a healthy volunteer cohort. *Npj Genomic Medicine*, *5*(46). https://doi.org/10.1038/s41525-020-00153-w
  - 18. Walsh, R., Thomson, K. L., Ware, J. S., Funke, B. H., Woodley, J., McGuire, K. J., Mazzarotto, F., Blair, E., Seller, A., Taylor, J. C., et al. (2017). Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples. *Genetics in Medicine*, 19(2), 192–203. https://doi.org/10.1038/gim.2016.90
    - 19. Shawky, R. M., El-Awady, M. Y., Elsayed, Solaf M., & Hamadan, G. E. (2011). Consanguineous matings among Egyptian population. *The Egyptian Journal of Medical Human Genetics*, *12*, 157–163. <u>https://doi.org/10.1016/j.ejmhg.2011.07.001</u>
  - 20. Shawky, R. M., Elsayed, N. S., Ibrahim, D. S., & Seifeldin, N. S. (2012). Profile of genetic disorders prevalent in northeast region of Cairo, Egypt. *Egyptian Journal of Medical Human Genetics*, 13(1), 45–62. https://doi.org/10.1016/j.ejmhg.2011.10.002
  - 21. Walsh, R., Buchan, R., Wilk, A., John, S., Felkin, L. E., Thomson, K. L., Chiaw, T. H., Chin, C., Loong, W., Pua, C. J., et al. (2017). Defining the genetic architecture of hypertrophic cardiomyopathy: re-evaluating the role of non-sarcomeric genes. *European Society of Cardiology*, 38, 3461–3468. https://doi.org/10.1093/eurheartj/ehw603
    - 22. de Marvao, A., Dawes, T. J. W., Shi, W., Durighel, G., Rueckert, D., Cook, S. A., & O'Regan, D. P. (2015). Precursors of hypertensive heart phenotype develop in healthy adults A High-Resolution 3D MRI Study. *JACC: Cardiovascular Imaging*. https://doi.org/10.1016/j.jcmg.2015.08.007
  - 23. Pua, C. J., Bhalshankar, J., Miao, K., Walsh, R., John, S., Lim, S. Q., Chow, K., Buchan, R., Soh, B. Y., Lio, P. M., et al. (2016). Development of a Comprehensive Sequencing Assay for Inherited Cardiac Condition Genes. *Journal of Cardiovascular Translational Research*, 9(1), 3–11. https://doi.org/10.1007/s12265-016-9673-5
- 24. Ingles, J., Goldstein, J., Thaxton, C., Caleshu, C., Corty, E. W., Crowley, S. B., Dougherty, K., Harrison, S. M., McGlaughon, J., Milko, L. v., et al. (2019). Evaluating the Clinical Validity of Hypertrophic Cardiomyopathy Genes. *Circulation: Genomic and Precision Medicine*, *12*(2), 57–64. https://doi.org/10.1161/CIRCGEN.119.002460
  - 25. Walsh, R., Offerhaus, J. A., Tadros, R., & Bezzina, C. R. (2021). Minor hypertrophic cardiomyopathy genes, major insights into the genetics of cardiomyopathies. *Nature Reviews Cardiology*, 1–17. https://doi.org/10.1038/s41569-021-00608-2
- 802 26. Maron, B. J., Maron, M. S., & Semsarian, C. (2012). Genetics of hypertrophic 803 cardiomyopathy after 20 years: Clinical perspectives. In Journal of the American 804 (Vol. College of Cardiology 60, Issue 8, pp. 705–715). 805 https://doi.org/10.1016/j.jacc.2012.02.068
- 27. Whiffin, N., Minikel, E., Walsh, R., O/'Donnell-Luria, A. H., Karczewski, K., Ing, A. Y.,
  Barton, P. J. R., Funke, B., Cook, S. A., MacArthur, D., et al. (2017). Using high-

808 809

810

811

812

813

820

821 822

823

824

825

826

827

828 829

830

831

832

833 834

835

836

837

838

839

840

841

842

843

844

845

846

847

848

849

850

851

852

853 854

855

856

resolution variant frequencies to empower clinical genome interpretation. *Genetics in Medicine*, *19*(10), 1151–1158. http://dx.doi.org/10.1038/gim.2017.26

- 28. Whiffin, N., Walsh, R., Govind, R., Edwards, M., Ahmad, M., Zhang, X., Tayal, U., Buchan, R., Midwinter, W., Wilk, A. E., et al. (2018). CardioClassifier: disease- and gene-specific computational decision support for clinical genome interpretation. *Genetics in Medicine*, *20*(10), 1246–1254. https://doi.org/10.1038/gim.2017.258
- 814 29. Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., 815 Hegde, M., Lyon, E., Spector, E., et al. (2015). Standards and guidelines for the 816 interpretation of sequence variants: a joint consensus recommendation of the 817 American College of Medical Genetics and Genomics and the Association for 818 Molecular Pathology. Genetics in Medicine, 17(5). 405-423. 819 https://doi.org/10.1038/gim.2015.30
  - Carrier, L., Mearini, G., Stathopoulou, K., & Cuello, F. (2015). Cardiac myosin-binding protein C (MYBPC3) in cardiac pathophysiology. In *Gene* (Vol. 573, Issue 2, pp. 188– 197). https://doi.org/10.1016/j.gene.2015.09.008
  - 31. Carrier, L. (2021). Targeting the population for gene therapy with MYBPC3. Journal of Molecular and Cellular Cardiology, 150(September 2020), 101–108. https://doi.org/10.1016/j.yjmcc.2020.10.003
  - 32. Kelly, M. A., Caleshu, C., Morales, A., Buchan, J., Wolf, Z., Harrison, S. M., Cook, S., Dillon, M. W., Garcia, J., Haverfield, E., et al. (2018). Adaptation and validation of the ACMG / AMP variant classification framework for MYH7 -associated inherited cardiomyopathies : recommendations by ClinGen 's Inherited Cardiomyopathy Expert Panel. *Genetics in Medicine : Official Journal of the American College of Medical Genetics*, 20(3), 351–359. https://doi.org/10.1038/gim.2017.218
    - 33. Walsh, R., Tadros, R., & Bezzina, C. R. (2020). When genetic burden reaches threshold. *European Heart Journal*, *41*(39). https://doi.org/10.1093/eurheartj/ehaa269
    - 34. Mazzarotto, F., Girolami, F., Boschi, B., Barlocco, F., Tomberli, A., Baldini, K., Coppini, R., Tanini, I., Bardi, S., Contini, E., et al. (2019). Defining the diagnostic effectiveness of genes for inclusion in panels: the experience of two decades of genetic testing for hypertrophic cardiomyopathy at a single center. *Genetics in Medicine*, 21(2). https://doi.org/10.1038/s41436-018-0046-0
  - 35. Janin, A., Januel, L., Cazeneuve, C., Delinière, A., Chevalier, P., & Millat, G. (2021). Molecular Diagnosis of Inherited Cardiac Diseases in the Era of Next-Generation Sequencing: A Single Center's Experience Over 5 Years. *Molecular Diagnosis and Therapy*, 25(3). https://doi.org/10.1007/s40291-021-00530-w
  - 36. Alfares, A. A., Kelly, M. A., McDermott, G., Funke, B. H., Lebo, M. S., Baxter, S. B., Shen, J., McLaughlin, H. M., Clark, E. H., Babb, L. J., et al. (2015). Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity. *Genetics in Medicine : Official Journal of the American College of Medical Genetics*, 17(11), 880–888. https://doi.org/10.1038/gim.2014.205
  - 37. Lopes, L. R., Rahman, M. S., & Elliott, P. M. (2013). A systematic review and metaanalysis of genotype-phenotype associations in patients with hypertrophic cardiomyopathy caused by sarcomeric protein mutations. *Heart*, *99*(24), 1800–1811. https://doi.org/10.1136/heartjnl-2013-303939
  - 38. Olivotto, I., Girolami, F., Ackerman, M. J., Nistri, S., Bos, J. M., Zachara, E., Ommen, S. R., Theis, J. L., Vaubel, R. A., Re, F., et al. (2008). Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. *Mayo Clinic Proceedings*, 83(6), 630–638. https://doi.org/10.4065/83.6.630
- 39. Millat, G., Bouvagnet, P., Chevalier, P., Dauphin, C., Simon Jouk, P., da Costa, A.,
  Prieur, F., Bresson, J. L., Faivre, L., Eicher, J. C., et al. (2010). Prevalence and
  spectrum of mutations in a cohort of 192 unrelated patients with hypertrophic
  cardiomyopathy. *European Journal of Medical Genetics*, 53(5), 261–267.
  https://doi.org/10.1016/j.ejmg.2010.07.007

- 40. Ripoll-Vera, T., Gámez, J. M., Govea, N., Gómez, Y., Núñez, J., Socías, L., Escandell,
  Á., & Rosell, J. (2016). Clinical and Prognostic Profiles of Cardiomyopathies Caused
  by Mutations in the Troponin T Gene. *Revista Española de Cardiología (English Edition)*, 69(2). https://doi.org/10.1016/j.rec.2015.06.025
- 41. Gimeno, J. R., Monserrat, L., Pérez-Sánchez, I., Marín, F., Caballero, L., HermidaPrieto, M., Castro, A., & Valdés, M. (2009). Hypertrophic Cardiomyopathy. A Study of
  the Troponin-T Gene in 127 Spanish Families. *Revista Española de Cardiología*(*English Edition*), 62(12). https://doi.org/10.1016/s1885-5857(09)73545-5
- 42. Salazar-Mendiguchiá, J., Ochoa, J. P., Palomino-Doza, J., Domínguez, F., Diéz-López, C., Akhtar, M., Ramiro-León, S., Clemente, M. M., Pérez-Cejas, A., Robledo, M., et al. (2020). Mutations in TRIM63 cause an autosomal-recessive form of hypertrophic cardiomyopathy. *Heart*, *106*(17). https://doi.org/10.1136/heartjnl-2020-316913

875

876

877

878

883

884

885

886

887

888

889

890

891 892

893 894

895

896

897

898 899

900

901

902

903

904

905

906

907

908

909

910

- 43. Scott, E. M., Halees, A., Itan, Y., Spencer, E. G., He, Y., Azab, M. A., Gabriel, S. B., Belkadi, A., Boisson, B., Abel, L., et al. (2016). Characterization of Greater Middle Eastern genetic variation for enhanced disease gene discovery. *Nature Genetics*, 48(9), 1071–1076. https://doi.org/10.1038/ng.3592
- 44. Vanninen, S. U. M., Leivo, K., Seppälä, E. H., Aalto-Setälä, K., Pitkänen, O.,
  Suursalmi, P., Annala, A. P., Anttila, I., Alastalo, T. P., Myllykangas, S., et al. (2018).
  Heterozygous junctophilin-2 (JPH2) p. (Thr161Lys) is a monogenic cause for HCM
  with heart failure. *PLoS ONE*, *13*(9). https://doi.org/10.1371/journal.pone.0203422
  - 45. Claes, G. R. F., van Tienen, F. H. J., Lindsey, P., Krapels, I. P. C., Helderman-Van Den Enden, A. T. J. M., Hoos, M. B., Barrois, Y. E. G., Janssen, J. W. H., Paulussen, A. D. C., Sels, J. W. E. M., et al. (2016). Hypertrophic remodelling in cardiac regulatory myosin light chain (MYL2) founder mutation carriers. *European Heart Journal*, 37(23). https://doi.org/10.1093/eurheartj/ehv522
    - 46. Olson, T. M., Karst, M. L., Whitby, F. G., & Driscoll, D. J. (2002). Myosin light chain mutation causes autosomal recessive cardiomyopathy with mid-cavitary hypertrophy and restrictive physiology. *Circulation*, 105(20). https://doi.org/10.1161/01.CIR.0000018444.47798.94
  - 47. Caleshu, C., Sakhuja, R., Nussbaum, R. L., Schiller, N. B., Ursell, P. C., Eng, C., de Marco, T., Mcglothlin, D., Burchard, E. G., & Rame, J. E. (2011). Furthering the link between the sarcomere and primary cardiomyopathies: Restrictive cardiomyopathy associated with multiple mutations in genes previously associated with hypertrophic or dilated cardiomyopathy. *American Journal of Medical Genetics, Part A*, 155(9). https://doi.org/10.1002/ajmg.a.34097
  - 48. Osborn, D. P. S., Emrahi, L., Clayton, J., Tabrizi, M. T., Wan, A. Y. B., Maroofian, R., Yazdchi, M., Garcia, M. L. E., Galehdari, H., Hesse, C., et al. (2021). Autosomal recessive cardiomyopathy and sudden cardiac death associated with variants in MYL3. *Genetics in Medicine*, 23(4), 787–792. https://doi.org/10.1038/s41436-020-01028-2
  - 49. Jaafar, N., Gómez, J., Kammoun, I., Zairi, I., Amara, W. ben, Kachboura, S., Kraiem, S., Hammami, M., Iglesias, S., Alonso, B., & Coto, E. (2016). Spectrum of Mutations in Hypertrophic Cardiomyopathy Genes among Tunisian Patients. *Genetic Testing and Molecular Biomarkers*, *20*(11), 674–679. https://doi.org/10.1089/gtmb.2016.0187
  - 50. Ma, N., Zhang, J. Z., Itzhaki, I., Zhang, S. L., Chen, H., Haddad, F., Kitani, T., Wilson, K. D., Tian, L., Shrestha, R., et al. (2018). Determining the pathogenicity of a genomic variant of uncertain significance using CRISPR/Cas9 and human-induced pluripotent stem cells. *Circulation*, 138(23). https://doi.org/10.1161/CIRCULATIONAHA.117.032273
- 91251. Janin, A., Bessière, F., Chauveau, S., Chevalier, P., & Millat, G. (2018). First913identification of homozygous truncating CSRP3 variants in two unrelated cases with914hypertrophic915https://doi.org/10.1016/j.gene.2018.07.036

- 52. Lipari, M., Wypasek, E., Karpinski, M., Tomkiewicz-Pajak, L., Laino, L., Binni, F.,
  Giannarelli, D., Rubis, P., Petkow-Dimitrow, P., Undas, A., et al. (2020). Identification
  of a variant hotspot in MYBPC3 and of a novel CSRP3 autosomal recessive alteration
  in a cohort of Polish cases affected by hypertrophic cardiomyopathy. *Polish Archives*of *Internal Medicine*. https://doi.org/10.20452/pamw.15130
- 53. Harper, A. R., Goel, A., Grace, C., Thomson, K. L., Petersen, S. E., Xu, X., Waring, A.,
  Ormondroyd, E., Kramer, C. M., Ho, C. Y., et al. (2021). Common genetic variants and
  modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and
  expressivity. *Nature Genetics*, *53*(2). https://doi.org/10.1038/s41588-020-00764-0
  - 54. Tadros, R., Francis, C., Xu, X., Vermeer, A. M. C., Harper, A. R., Huurman, R., Kelu Bisabu, K., Walsh, R., Hoorntje, E. T., et al. (2021). Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect. *Nature Genetics*, *53*(2). https://doi.org/10.1038/s41588-020-00762-2
  - 55. Pua, C. J. B., Tham, N., Chin, C. W. L., Walsh, R., Khor, C. C., Toepfer, C. N., Repetti, G. G., Garfinkel, A. C., Ewoldt, J. F., Cloonan, P., et al. (2020). Genetic studies of hypertrophic cardiomyopathy in singaporeans identify variants in TNNI3 and TNNT2 that are common in Chinese patients. *Circulation: Genomic and Precision Medicine*. https://doi.org/10.1161/CIRCGEN.119.002823
    - 56. Wooten, E. C., Hebl, V. B., Wolf, M. J., Sarah, R., Orr, N., Draper, I., Calvino, J. E., Navin, K., Maron, M. S., Kullo, I. J., et al. (2013). Formin Homology 2 Domain Containing 3 (FHOD3) Variants Associated with Hypertrophic Cardiomyopathy. *Circulation Cardiovascular Genetics*, 6(1), 10–18. https://doi.org/10.1161/CIRCGENETICS.112.965277.Formin
      - 57. Gómez, J., Lorca, R., Reguero, J. R., Morís, C., Martín, M., Tranche, S., Alonso, B., Iglesias, S., Alvarez, V., Díaz-Molina, B., et al. (2017). Screening of the Filamin C Gene in a Large Cohort of Hypertrophic Cardiomyopathy Patients. *Circulation: Cardiovascular Genetics*, *10*(2). https://doi.org/10.1161/CIRCGENETICS.116.001584
      - 58. Valdés-Mas, R., Gutiérrez-Fernández, A., Gómez, J., Coto, E., Astudillo, A., Puente, D. A., Reguero, J. R., Álvarez, V., Morís, C., León, D., Martín, M., et al. (2014). Mutations in filamin C cause a new form of familial hypertrophic cardiomyopathy. *Nature Communications*, 5. https://doi.org/10.1038/ncomms6326
    - Almomani, R., Verhagen, J. M. A., Herkert, J. C., Brosens, E., van Spaendonck-Zwarts, K. Y., Asimaki, A., van der Zwaag, P. A., Frohn-Mulder, I. M. E., Bertoli-Avella, A. M., Boven, L. G., et al. (2016). Biallelic Truncating Mutations in ALPK3 Cause Severe Pediatric Cardiomyopathy. *Journal of the American College of Cardiology*, 67(5), 515–525. https://doi.org/10.1016/j.jacc.2015.10.093